Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5658 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 5 6 7 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Curetis–SEVERAL: investment, 201804 capital increase €4.1m offering of 854k new ordinary shares at €4.8/share to qualified EU + US investors 2018-04-27
Polyphor–Consilium: public relations, 201804 service existent international media relations by CSC 2018-04-27
Boehringer–Topas Therapeutics: immuno modulatory compounds, 201804– collab €na multi-y research + option agreem 2018-04-24
Bosch–Randox: point-of-care diagnostics, –201804 collab developm test panels for Vivalytic POC analyser 2018-04-21
Merck (DE)–P&G: investment, 201804 acquisition €3.4b in cash of Merck’s consumer healthcare by P&G 2018-04-19
AiCuris–Max Planck: anti-infectives, 2018004– collab discovery of antibiotics + virostatic compounds extending existent collab with MPI-MP 2018-04-18
InterAx Biotech–LeadXPro: cancer immunotherapy, 201804– collab €na drug discovery + optimisation of lead molecules targeting GPCRs 2018-04-18
Novartis–Pear Therapeutics: digital health, 201804– collab developm + commercialisation of prescripition digital therapeutics for drug abuse Sandoz 2018-04-18
Tizona Therapeutics–Minapharm: biopharma production, 201804– supply service cell line + process developm + production of therap antibody by ProBioGen 2018-04-18
Anasys Instruments–Bruker Corp: investment, 201804 acquisition of Anasys by Bruker 2018-04-17
DiaMan–GlucoMe: digital health, 201804– collab product integration of GlucoMe + DiaMan products + marketing in Central America by DiaMan 2018-04-17
DKSH–Bruker Corp: analytical instruments, 201804– distribution multi-product line of Bruker AXS in KR + AU + NZ + SG + ID by DKSH Technology 2018-04-17
Biovertis–Deinove: investment, 201804–201805 acquisition of Biovertis/Morphochem for €900k in 500k new shares + 8m warrants 2018-04-13
Enterprise Therapeutics–Novartis: investment, 201804 financing round Series B totalling £29m ($41m) incl co-lead investor Novartis Venture Fund 2018-04-12
Enterprise Therapeutics–SEVERAL: investment, 201804 financing round Series B £29m ($41m) co-led by Versant Ventures + NVF 2018-04-12
Knauer–Microsaic: mass spectrometry, 201804– collab integration of Microsaic’s compact MS techn in Knauer’s LC platform 2018-04-12
Petra Pharma–Evotec: drug development services, 201804– supply service €na support developm of Petra-01 through to IND 2018-04-11
Roivant–Arbutus Biopharma: RNA drugs, 201804– collab founding of jv Genevant Sciences to develop RNA drugs using LNP technology 2018-04-11
Baliopharm–Promethera: investment, 201804 acquisition €na of Baliopharm AG by Promethera Biosciences SA 2018-04-10
Boehringer–Biomax: bioinformatics, 201804– license multi-year for BioXM s/w + license extension for BioRS s/w 2018-04-10
Promethera–MacDougall Biomedical Communications: public relations, 201804 service existent by MacDougall 2018-04-10
AveXis–Novartis: investment, 201804–201805 acquisition $8.7b in cash of AveXis Inc by Novartis for $128/share 2018-04-09
Grünenthal–Univ Leuven: pain drugs, 201804– collab r+d non-opioid pain drugs with CD3 + LICR 2018-04-09
Polyphor–SEVERAL: investment, 201804–201805 IPO CHF155m (€130m) at SIX Swiss Exchange at CHF38/share 2018-04-09
Boehringer–OSE Immunotherapeutics: antibody cancer drug, 201804– collab + license ww OSE-172 €30m upfront+short-term + €1.1b milestones + royalties 2018-04-04
Bravos Biosciences–Arsanis: therapeutic antibody, 201804– license pre-clin develop ww excl to ASN200 program + option further developm to BB100 LLC 2018-04-04
LCF Rothschild–Andera Partners: investment, 201804 management buy-out of EdRIP by employees + renaming to Andera Partners 2018-04-04
Brainomix–Boehringer: investment, 201804 financing round totalling £7m incl new + co-investor BIVF 2018-04-03
Brainomix–SEVERAL: investment, 201804 financing round £7m led by Parkwalk Advisors + incl BIVF + Chimera Partners + Oxford Univ 2018-04-03
Macrolide–Advent Venture Partners: investment, 201804 financing round totalling $20m incl existing investor Advent Life Sciences 2018-04-01
Macrolide–Bertarelli Group: investment, 201804 financing round totalling $20m incl existing investor Gurnet Point Capital 2018-04-01
Macrolide–GSK: investment, 201804 financing round totalling $20m incl existing investor SR One 2018-04-01
Macrolide–Novartis: investment, 201804 financing round totalling $20m incl existing investor Novartis Venture Fund 2018-04-01
Macrolide–Roche: investment, 201804 financing round totalling $20m incl existing investor Roche Ventures 2018-04-01
Macrolide–SEVERAL: investment, 201804 financing round $20m led by existing investors Advent LS + Gurnet Point + Novartis + Roche + SR One 2018-04-01
Novartis–GSK: investment, 201803– acquisition $13b of 36.5% stake of Novartis in OTC joint venture giving GSK 100% ownership 2018-03-27
PITBUL project–EU (govt): grant, 201803–2020 Horizon 2020 grant €3.8m to develop ultrafast PoC tuberculosis diagnostic platform 2018-03-24
NMD Pharma–ABP (NL): investment, 201803 financing round Series A totalling €38m incl new + lead investor Inkef Capital 2018-03-23
NMD Pharma–Lundbeck: investment, 201803 financing round Series A totalling €38m incl existing + co-investor Lundbeckfonden Emerge 2018-03-23
NMD Pharma–Novo Group: investment, 201803 financing round Series A totalling €38m incl existing + co-investor Novo Seeds 2018-03-23
NMD Pharma–Roche: investment, 201803 financing round Series A totalling €38m incl new + co-investor Roche Venture Fund 2018-03-23
NMD Pharma–SEVERAL: investment, 201803 financing round Series A €38m led by new investor Inkef Capital + incl RVF + Novo Seeds + Lundbeckfonden 2018-03-23
MorphoSys–SEVERAL: investment, 201803–201804 US IPO $208m+$31m with 8.3m+1.245m ADSs at $25.04/ADS + listing at Nasdaq Global Market 2018-03-22
Aton–Grifols: investment, 201803– acquisition 100% of Haema for €220 on a debt free basis by Grifols from Aton GmbH 2018-03-20
Novartis–Harvard Univ: drug delivery technology, 201803– collab develop biomaterial systems for delivery of cancer immuntherapies NIBR + Wyss + Dana 2018-03-20
Robert Bosch Hospital–bio.logis: genetic software, 201803– supply implementation of bio.logis GIMS IT platform at RBK 2018-03-20
Bruker Corp–KAUST: magnet resonance technology, 201803– collab establ KAUST-Bruker Center of Excellence in Magnetic Resonance 2018-03-18
KAUST–Bruker Corp: magnetic resonance technology, 201803 supply 500 MHz super wide-bore MRI spectrometer at KAUST-Bruker CoE in Magnetic Resonance 2018-03-18
KAUST–Bruker Corp: magnetic resonance technology, 201803 supply 900 MHz wide-bore NMR spectrometer at KAUST-Bruker CoE in Magnetic Resonance 2018-03-18
KAUST–Bruker Corp: magnetic resonance technology, 201803 supply 950 MHz NMR spectrometer at KAUST-Bruker CoE in Magnetic Resonance 2018-03-18
KAUST–Bruker Corp: magnetic resonance technology, 201803 supply DNP NMR spectrometer at KAUST-Bruker CoE in Magnetic Resonance 2018-03-18
Biocatalysts Ltd–BRAIN: investment, 201803 acquisition of majority stake in Biocatalysts Ltd by BRAIN AG 2018-03-17
Mérieux–Sartorius: bioreactors, 201803 supply of single-use viral vector manufacturing package to ABL Europe in Strasboug by SSB 2018-03-16
Prexton Therapeutics–Lundbeck: investment, 201803– acquisition €100m upfront + €805m developm + sales milestones ANNOUNCED 2018-03-16
Siemens–SEVERAL: investment, 201803 IPO €4.2b of Siemens Healthineers AG at FSE floating 150m (15% of) shares at €28/share 2018-03-16
Boehringer–Vanderbilt Univ: MCL1 inhibitors, 201803– collab expansion r+d of MCL1 inhibitors for cancer 2018-03-13
Danaher–KAUST: microscopy, 201803– collab establ KAUST-Leica Center of Excellence in Optical Microscopy 2018-03-12
KAUST–Danaher: microscopy, 201803 supply SP8 confocal platform to new KAUST-Leica Center of Excellence in Optical Microscopy 2018-03-12
Medical Univ Vienna–bio.logis: genetic software, 201803 collab use of bio.logis GIMS.DRM with safety code card at MUW 2018-03-12
Atomwise–SEVERAL: investment, 201803 financing round Series A $45m co-led by Monsanto GV + DCVC (Data Collective) + B Capital Group 2018-03-07
Compugen–JSR Corp: cell line development, 201803– license to use Selexis’ SUREtechnology for developm of cancer antibody drugs incl COM701 2018-03-07
Novartis–Science 37: clinical research, 201803– collab 3y expansion up to 10 decentralised clinical trials 2018-03-07
Ventech–SEVERAL: investment, 201803 first closing €140m of Ventech Capital V fund with €200m target size 2018-03-07
Magenta Therapeutics–Heidelberg Pharma: antibody-drug conjugates, 201803– collab developm of ADCs for bone marrow transplant using ATAC platform 2018-03-05
abcr GmbH–Enzymicals: enzymes, 201803– collab distribution expansion ww catalogue sale of selected enzymes + enzyme-produced chemicals 2018-03-01
Affiris–PR&D: public relations, 201803 service existent by PR&D – Public Relations for Research & Education 2018-03-01
Heidelberg Pharma–MC Services: public relations, 201803 service existent by MC Services 2018-03-01
Heidelberg Pharma–Univ Texas: personalised medicine, 201803– license for Dx + Tx of cancer patients w RNA polymerase II deletion 2018-03-01
Berlin Cures–Russo Partners: public relations, 201802 service existent by Russo Partners 2018-02-26
Bruker Corp–Evosep: liquid chromatography, –201802 collab product integration of timsTOF Pro MS + Evosep One LC for HT clinical proteomics 2018-02-26
Xencor–JSR Corp: cell line development, 201802– four commercial licenses to use Selexis’ SUREtechnology for developm of bispecific antibodies 2018-02-26
IRM² Infrarot Mikroskopie und Messtechnik GmbH–Bruker Corp: investment, 201802 acquisition €na of IRM² by Bruker 2018-02-22
Aimmune Therapeutics–Nestlé: investment, 201802–201803 public offering totalling $202.4m incl $30m from existing investor Nestlé Health Science 2018-02-20
Aimmune Therapeutics–SEVERAL: investment, 201802–201803 public offering $176m+$26.4m net $190m with 5.5m+825k shares common stock at $32/share 2018-02-20
Cullinan Oncology–MAB Discovery: antibody cancer drug, 201802– collab developm of MAbs based on MAB Discovery’s discovery platform 2018-02-20
Gain Therapeutics–SEVERAL: investment, 201802 investment spin-off of Minorix’ SEE-Tx platform as Gain Therapeutics with Swiss investors + TiVenture 2018-02-20
ABAC Therapeutics–SEVERAL: investment, 201802 financing round Series A €16m led by Pontifax + incl GHSF + Caixa Capital Risc + Debiopharm + Ferrer 2018-02-15
Addex–SEVERAL: investment, 201802–201803 private placement CHF40m with 12.78m new shares at CHF3.13/share plus 0.4 warrants at CHF3.43 2018-02-15
Flatiron Health–Roche: investment, 201802–201804 acquisition $1.9b of remaining 87.4% not already owned by Roche 2018-02-15
Mologen–SEVERAL: investment, 201802–20103 capital increase €4.99m with 2.36m new shares at €2.12/share to existing + new investors 2018-02-15
Pieris–SEVERAL: investment, 201802 public offering $50.6m with 5.5m+825k common shares at $8/share 2018-02-13
Swiss Medical Imaging Investment–RAD-x: investment, 201802 acquisition of SMII by RAD-x 2018-02-13
Affimed–SEVERAL: investment, 201802 public offering $26.5m ($24.5m net) with 12.5m+1.725m common shares at $2/share 2018-02-12
Lonza–Kirkstall: cell culture system, 201802– collab ww marketing + distribution of Quasi Vivo System by Lonza 2018-02-12
Pieris–Trophic Communications: public relations, 201802 service existent media relations by Trophic 2018-02-09
Seattle Genetics–Pieris: cancer immunotherapy, 201802– collab $30m upfront + $1.2b milestones + royalties developm antibody-anticalin fusion proteins 2018-02-09
Pfizer–Genedata: bioinformatics, 201802– supply license for Genedata Bioprocess enterprise platform to Pfizer Inc 2018-02-08
Thermo Fisher–Endress+Hauser: lab automation, 201802 collab product integration of AJ’s CyBio FeliX system in cell-free DNA extraction device 2018-02-07
Servier–ImmunoQure: therapeutic antibodies, 201802– collab developm of INF-alpha human autoantibody for autoimmune diseases 2018-02-06
Faron Pharmaceuticals–Lyomark Pharma: Traumakine, 201802– supply contract manfucturing by Lyocontract GmbH 2018-02-05
Faron Pharmaceuticals–Rentschler: Traumakine, 201802 supply existent contract manfucturing by Rentschler Biopharma SE 2018-02-05
TraitGenetics–SGS: investment, 201802 acquisition of TraitGenetics GmbH by SGS 2018-02-02
Cytosurge–Lab Automation Network: cell analysis technology, 201802– collab product integration to offer automated single-cell biology applications 2018-02-01
REPO-TRIAL project–Biocrates: drug respositioning, 201802–202301 collab Biocrates is industry member of Horizon 2020 project 2018-02-01
REPO-TRIAL project–EU (govt): grant, 201802–202301 Horizon 2020 grant €5.6m for in silico trial-based drug repositioning 2018-02-01
REPO-TRIAL project–HM Pharma Consultancy: drug respositioning, 201802–202301 collab HMPC is industry member of Horizon 2020 project 2018-02-01
REPO-TRIAL project–SomaLogic: drug respositioning, 201802–202301 collab SomaLogic UK is industry member of Horizon 2020 project 2018-02-01
Silvacx–Merck (DE): nanoparticle technology, 201802– license excl to Silvacx delivery technology for cancer immunotherapy 2018-02-01
Silvacx–North Rhine-Westphalia (govt): grant, 201802– r+d grant €1.93m 3 years to develop Silvacx technology 2018-02-01
Biotest–Credit Suisse: financial services, 201704 supply service financial advisor with regard to sale of Biotest AG to Ceat Group (CN) 2018-01-31
next pagenext page 1 2 3 ... 5 6 7 ... 55 56 57  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top